Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Muta...(seven mutationsin codons 12 and 13 of th...)

The TheraScreen EGFR 29 Test is designed to enable detection of 29 of the most common somatic mutations in the EGFR gene and detects mutations with greater sensitivity than sequencing. Recent studies in non-small cell lung cancer have shown that some patients carry somatic mutations in the epidermal growth factor receptor (EGFR) gene. These mutations may correlate with responsiveness to the EGFR tyrosine kinase inhibitors, with some mutations having a sensitizing effect and others being linked to resistance. Ongoing trials in metastatic NSCLC are investigating whether such a test could aid doctors in selecting lung cancer patients suitable for first line treatment

with EGFR tyrosine kinase inhibitors, such as Tarceva, in the future.

About DxS

DxS is a UK-based personalized medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. DxS offers products, technology and services to the healthcare industry to enable the delivery of safe and effective medicines. Working predominantly in the field of cancer, DxS has a range of companion diagnostic and research kits that detect mutations in oncogenes associated with cancer drug response. The TheraScreen(R) range of CE Mark certified diagnostic products includes kits that detect mutations in the EGFR and K-RAS genes. Tumor mutation products are available for research use for EGFR, RAS, RAF, BCR-ABL and other genes that show a correlation between patient mutation status and drug response. DxS also provides a genetic analysis service to support clinical development. For more information, visit http://www.dxsdiagnostics.com.

'/>"/>